Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

Executive Summary

As many as five PD-1/L1 inhibitors will be approved for second-line metastatic disease by the end of 2017, but AstraZeneca hopes to stand apart with the combination of Imfinzi (durvalumab) with its CTLA-4 inhibitor tremelimumab.

Advertisement

Related Content

AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer
Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel